Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.

Vandetanib is a multi-targeted receptor tyrosine kinase inhibitor that is in clinical development for the treatment of solid tumours. This preclinical study examined the inhibition of two key signalling pathways (VEGFR-2, EGFR) at drug concentrations similar to those achieved in the clinic, and thei...

Full description

Bibliographic Details
Main Authors: Brave, SR, Odedra, R, James, N, Smith, N, Marshall, G, Acheson, K, Baker, D, Howard, Z, Jackson, L, Ratcliffe, K, Wainwright, A, Lovick, S, Hickinson, D, Wilkinson, R, Barry, S, Speake, G, Ryan, A
Format: Journal article
Language:English
Published: 2011

Similar Items

Similar Items